Faecal Microbiota Transplantation And Other Novel Therapeutic Microbial Manipulation Strategies In Inflammatory Bowel Disease
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
There is growing interest in the role of microbial-based strategies including faecal microbiota transplantation (FMT) for the treatment of inflammatory bowel disease. This project will develop such strategies into valid treatment options through a combination of clinical & basic science work including (1) characterising viral & fungal factors of importance, (2) evaluation of novel orally-delivered formulations of FMT, and (3) development of better defined, more reproducible microbial treatments.
From Bench To Bedside: A New Treatment For Chronic Rhinosinusitis
Funder
National Health and Medical Research Council
Funding Amount
$2,360,520.00
Summary
My research focuses on diseases of the upper airways, in particular chronic relapsing infections and inflammation of the nose and sinus mucosa and on improving wound healing after surgery. My research is translational, aimed at defining new treatments for these diseases. I have invented novel products that improve wound healing after surgery and instruments that help surgeons perform their surgeries in a better and safer way.
Systems-based Study, Intervention, Diagnosis And Control Of Gastrointestinal Parasites
Funder
National Health and Medical Research Council
Funding Amount
$2,538,220.00
Summary
Gastrointestinal parasites cause billions of infections and hundreds of thousand of deaths globally each year. Even in developed countries, these parasites remain an important public health risk, through the cost of their control, the acute impacts of infection and their contribution to post-infectious irritable bowel syndrome and chronic fatigue. My team employs cutting-edge methods to improve their diagnosis, surveillance, treatment and control.
Enhancing Control Of Enteric Bacteria Through Pathogen Genomics
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Bacteria part of the Enterobacteriaceae family are responsible for causing significant enteric disease in Australia and internationally. Compounding the public health threat posed by these enteric bacteria is the rise in antimicrobial resistance, which limits treatment options. This project has three complementary research objectives; 1) to investigate new control strategies; 2) to better understand outbreak dynamics and; 3) to explore how bacteria are causing new disease in humans.
Protecting The Gut: A Novel Therapeutic Avenue For Reducing The Damaging Consequences Of Obesity
Funder
National Health and Medical Research Council
Funding Amount
$570,205.00
Summary
Most patients with obesity develop gut dysfunction. Symptoms including constipation and diarrhoea often present before other common comorbidities like diabetes and heart disease, suggesting that early pathology in obesity may begin in the gut. This research project aims to understand the mechanisms through which gut dysfunction develops in obese mice and human patients, and test a clinically approved compound that has demonstrated gut protective properties for the first time in obesity.
Inflammation is essential to help fight infection and repair tissues. However when overactive it causes diseases such as psoriasis, arthritis and inflammatory bowel disease. Less well known, inflammation also helps drive development of cancers. My research aims to understand inflammatory signalling at the molecular and organism level. Experience has shown that this knowledge can be translated to improve existing therapies or generate new ones, and that is the ultimate aim of my research.
Improving Reproductive Health Through Infectious Diseases Research
Funder
National Health and Medical Research Council
Funding Amount
$1,957,108.00
Summary
Infectious diseases that impact upon reproductive health remain a major problem worldwide. This proposal will examine human papillomavirus infection, the role of the human microbiota in a number of conditions (necrotising enterocolitis, bacterial vaginosis, and human papillomavirus infection), and antibiotic resistance in sexually transmitted infections. The knowledge generated will be used to improve diagnostics.
Mechanisms Of Cell Death Driven Inflammation In The Skin
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Inflammatory skin conditions are a leading cause of disease. Current therapies treat symptoms not causes of inflammation. Skin cells constantly interact with cells of the immune system, and with a diverse array of helpful and harmful microorganisms. My data suggest a role of the skin flora and resident immune cells in the initiation and progression of skin disease. I will investigate how the microbiota and immune cells can initiate cell death and drive excessive immune responses in the skin.
Leaving No One Behind: Community-driven Approaches To Eliminate HIV In Australia
Funder
National Health and Medical Research Council
Funding Amount
$1,562,250.00
Summary
Eliminating HIV from Australia is possible with effective HIV prevention methods like treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). However there are inequities in our HIV response with declines of new infections in Australian-born men who have sex with men but not in overseas-born Australian men. This program uses crowdsourcing (sharing solutions from the community to eliminate HIV) and evaluates the value of the proposed solutions, to inform HIV policy.
Computational Modelling To Understand Early-stage Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Rather than attempting to reverse neurodegeneration, therapeutic strategies must target the earliest possible stages of disease, when treatments have the potential to prevent or slow down pathological progression. The proposed project will employ computational modelling using functional MRI to deliver highly efficient and sensitive markers of Familial Alzheimer’s disease and Huntington’s disease progression to inform when in the progression of disease clinical trials should take place.